Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease.
One of the consistent findings in the brains of Alzheimer's Disease (AD) patients is loss of cholinergic function. The cholinergic approach to treatment of AD involves counteracting this loss in cholinergic activity by pharmacological intervention to increase cholinergic transmission. The cognitive effects of acetylcholine are mediated via the muscarinic M1 receptor. Direct stimulation of this receptor using muscarinic M1 agonists improves cognition in animal models and improves performance in cognitive tests in Alzheimer's patients. Alternatively, antagonists of central presynaptic M2 receptors improves cognition by increasing the central release of acetylcholine. Both approaches require high selectivity for one muscarinic receptor sub-type both for efficacy and to avoid cholinergic side effects. In this review summarizes recent progress in the identification and characterization of selective muscarinic receptor ligands for the treatment of Alzheimer's disease.
Clader
John W
JW
Schering-Plough Research Institute 2015 Galloping Hill Road Kenilworth, NJ 07033, USA. john.clader@spcorp.com
Wang
Yuguang
Y
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D006801:Humans; D015394:Molecular Structure; D018721:Muscarinic Agonists / Q000737:chemistry / Q000627:therapeutic use*; D018727:Muscarinic Antagonists / Q000737:chemistry / Q000627:therapeutic use*; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000627:therapeutic use
D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D011976:Receptors, Muscarinic